The role of parthenolide in intracellular signalling processes: Review of current knowledge

Current Signal Transduction Therapy

Volumn 3, Issue 2, 2008, Pages 82-87

  Bedoya, Luis Miguel ^a   Abad, María José ^a   Bermejo, Paulina ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Parthenolide; Sesquiterpene lactones; Tanacetumparthenium

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; CASPASE 3; CISPLATIN; CYCLIN D1; FENRETINIDE; FULVESTRANT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; I KAPPA B; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PACLITAXEL; PARTHENOLIDE; PHOSPHATIDYLSERINE; PRASTERONE; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; SABARUBICIN; SESQUITERPENE LACTONE; STRESS ACTIVATED PROTEIN KINASE; SULINDAC; TANACETUM PARTHENIUM EXTRACT; TUMOR NECROSIS FACTOR ALPHA; UROKINASE;

ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BONE DISEASE; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL PROLIFERATION; CELL TRANSFORMATION; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME RELEASE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; HEART PROTECTION; HEPATITIS C; HUMAN; IC 50; INNATE IMMUNITY; KIDNEY INJURY; LEISHMANIASIS; LOW DRUG DOSE; LUNG METASTASIS; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; MEMBRANE DEPOLARIZATION; MONOTHERAPY; NEUTROPHIL; NONHUMAN; OSTEOLYSIS; OXIDATIVE STRESS; PHOTOAGING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 54949145019     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436208784223134     Document Type: Review

References (47)

1. Heinrich M. Ethnobotany and its role in drug development. Phytother Res 2000; 14: 479-88.
2. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 2005; 4: 206-20.
3. Abad MJ, Guerra JA, Bermejo P. Phytochemistry and pharmacology of Tanacetum: recent developments. In: Govil JN, Singh VK, Sharma RKR Eds, Recent Progress in Medicinal Plants, USA, Studium Press LLC 2008; Vol 20: 301-51.
4. Flora SJ. Role of free radicals and antioxidants in health and disease. Cell Moll Biol 2007; 53: 1-2.
5. Atish TP, Vikrantsinh MG, Kamlesh KB. Modulating TNF-α signalling with natural products. Drug Discov Today 2006; 11: 725-32.
6. Li-Weber M, Palfi K, Giaisi M, Krammer PH. Dual role of anti-inflammatory sesquiterpene lactone: regulation of the life and death by parthenolide. Cell Death Differ 2005; 12: 408-9.
7. Parada-Turska J, Paduch R, Majdan M, Kandefer-Szerszca M, Rzeski W. Anti-proliferative activity of parthenolide against three human cancer cell lines and human umbilical vein endothelial cells. Pharmacol Rep 2007; 59: 233-7.
8. Wu C, Chen F, Rushing JW, et al. Antiproliferative activities of parthenolide and golden feverfew extract against three humam cancer cell lines. J Med Food 2006; 9: 55-61.
9. Zunino SJ, Ducore JM, Storms DH. Parthenolide induces significant apoptosis and production of reactive oxygen species in high-risk pre-B leukaemia cells. Cancer Lett 2007; 254: 119-27.
10. Steele AJ, Jones DT, Ganeshagurn K, et al. The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukaemia cells. Leukemia 2006; 20: 1073-9.
11. Wang W, Adachi M, Kawamura R, et al. Parthenolide-induced apoptosis in multiple myeloma cells involves reactive oxygen species generation and cell sensitivity depends on catalase activity. Apoptosis 2006; 11: 2225-35.
12. Chen ZC, Li QB, Shao J, et al. Proliferation inhibiting and apoptosis inducing effects of parthenolide on human multiple myeloma cells. Zhonghua Yi Xue Za Zhi 2006; 86: 1993-6.
13. Zhong D, Zhu R, Zhong M. Effects of parthenolide on the activity and expression of urokinase type plasminogen activator in PGCL3 cells. Zhong Yao Cai 2005; 28: 800-2.
14. Won YK, Ong CN, Shen HM. Parthenolide sensitizes ultraviolet (UV)-B-induced apoptosis via protein kinase C-dependent pathways. Carcinogenesis 2005; 26: 2149-56.
15. Garcia AJ, Lindenmeyer MT, Merfort I. Role of cysteine residues of p65/ NF-κB on the inhibition by the sesquiterpene lactone parthenolide and N-ethyl maleimide, and on its transactivating potential. Life Sci 2004; 75: 841-56.
16. Zhang S, Lin ZN, Yang CF, Shi X, Ong CN, Shen HM. Suppresed NF-κB and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-α-induced apoptosis in human cancer cells. Carcinogenesis 2004; 25: 2191-9.
17. Yip-Schneider MT, Nakshatri H, Sweeny CJ, Marshall MS, Wiebke EA, Schmidt CM. Parthenolide and sulindac cooperate to mediate growth suppresion and inhibit the nuclear factor-κB pathway in pancreatic carcinoma cells. Mol Cancer Ther 2005; 4: 587-94.
18. Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukaemia stem and progenitor cells. Blood 2005; 105: 4163-9.
19. Oka D, Nishimura K, Shiba M, et al. Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-κB. Int J Cancer 2007; 120: 2576-81.
20. Kishida Y, Yoshikawa H, Myoui A. Parthenolide, a natural inhibitor of nuclear factor-κB, inhibits lung colonization of murine osteosarcoma cells. Clin Cancer Res 2007; 13: 59-67.
21. Nakshatri H, Rice SE, Bhat-Nakshatri P. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumour necrosis factor-related apoptosis-inducing ligand through sustained activation of C-jun-N-terminal kinase. Oncogene 2004; 23: 7330-44.
22. Sweeny CJ, Mehrotra S, Sadaria MR, et al. The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol Cancer Ther 2005; 4: 1004-12.
23. Fonrose X, Ausseil F, Soleilhac E, et al. Parthenolide inhibits tubulin carboxypeptidase activity. Cancer Res 2007; 67: 3371-8.
24. Miglietta A, Bozzo F, Gabriel L, Bocca C. Microtubule-interfering activity of parthenolide. Chem Biol Interact 2004; 149: 165-73.
25. Gopal YN, Arora TS, Van Dyke MW. Parthenolide specifically repletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated. Chem Biol 2007; 14: 813-23.
26. Yip-Schneider MT, Wu H, Ralstin M, et al. Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Mol Cancer Ther 2007; 6: 1736-44.
27. Ralstin MC, Gage EA, Yip-Schneider MT, Klein PJ, Wiebke EA, Schmidt CM. Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest. Mol Cancer Res 2006; 4: 387-99.
28. Taguchi T, Takao T, Iwasaki Y, Nishiyama M, Asaba K, Hashimoto K. Suppressive effects of dehydroepiandrosterone and the nuclear factor κB inhibitor parthenolide on corticotroph tumor cell growth and function in vitro and in vivo. J Endocrinol 2006; 188: 321-31.
29. Park JH, Liu L, Kim IH, Kim JH, You RR, Kim DG. Identification of the genes involved in enhanced fenretinide-induced apoptosis by parthenolide in human hepatoma cells. Cancer Res 2005; 65: 2804-14.
30. Wang LC, Woon ST, Baguley BC, Ching LM. Inhibition of DMXAA-induced tumor necrosis factor production in murine splenocyte cultures by NF-κB inhibitors. Oncol Res 2006; 16: 1-14.
31. Bellarosa D, Binaschi M, Maggi CA, Goso C. Sabarubicin (MEN 10755) and paclitaxel show different kinetics in nuclear factor-κB (NF-κB) activation: effect of parthenolide on their cytotoxicity. Anticancer Res 2005; 25: 2139-28.
32. Riggins RB, Zwart A, Nehra R, Clarke R. The nuclear factor κB inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther 2005; 4: 33-41.
33. Francescato HD, Costa RS, Scavone C, Coimbra TM. Parthenolide reduces cisplatin-induced renal damage. Toxicology 2007; 230: 64-75.
34. Nam NH. Naturally occurring NF-κB inhibitors. Mini Rev Med Chem 2006; 6: 945-51.
35. Yuan G, Wahlquist ML, He G, Yang M, Li D. Natural products as anti-inflammatory activity. Asia Pac J Clin Nutr 2006; 15: 143-52.
36. Saadane A, Masters S, Didonato J, Li J, Berger M. Parthenolide inhibits IκB kinase, NF-κB activation and inflammatory response in cystic fibrosis cells and mice. Am J Respir Cell Mol Biol 2007; 36: 728-36.
37. Herrera F, Marin V, Rodriguez-Blanco J, Garcia-Santos C, Antolin I, Rodriguez C. Intracellular redox state regulation by parthenolide. Biochem Biophys Res Commun 2005; 332: 321-5.
38. Li X, Cui X, Li Y, Fitz Y, Hsu L, Eichacker PQ. Parthenolide has limited effects on nuclear factor-κB increases and worsens survival in hipopolysaccharide-challenged C57BL/GJ mice. Cytokine 2006; 33: 299-308.
39. Lopez-Franco G, Hernandez-Vargas P, Ortiz-Muñoz G, et al. Parthenolide modulates the NF-κB-mediated inflammatory responses in experimental atherosclerosis. Artherioscler Thromb Vasc Biol 2006; 26: 1864-70.
40. Gomez-Hernandez A, Martin-Ventura JL, Sanchez-Galan E, et al. Overexpression of COX-2, prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-κB. Atherosclerosis 2006; 187: 139-49.
41. Kurdi M, Bowers MC, Dado J, Booz GW. Parthenolide induces a distinct pattern of oxidative stress in cardiac myocytes. Free Radic Biol Med 2007; 42: 474-81.
42. Yao H, Tang X, Shao X, Feng L, Wu N, Yao K. Parthenolide protects humans lens epithelial cells from oxidative stress-induced apoptosis via inhibition of activation of caspase-3 and caspase-9. Cell Res 2007; 17: 565-71.
43. Yip KH, Zheng MH, Fang HT, Steer JH, Joyce DA, Xu J. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-κB activity. J Bone Miner Res 2004; 19: 1905-16.
44. Hwang DR, Wu YS, Chang CW, et al. Synthesis and antiviral activity of a series of sesquiterpene lactones and analogues in the subgenomic HCV replicon system. Bioorg Med Chem 2006; 14: 83-91.
45. Tiuman TS, Ueda-Nakamura T, Garcia-Cortez DA, et al. Anti leishmanial activity of parthenolide, a sesquitespene lactone isolated from Tanacetum parthenium. Antimicrob Agents Chemother 2005; 49: 176-82.
46. Tanaka K, Hasegawa J, Asamitsu K, Okamoto T. Prevention of the ultraviolet B-mediated skin photoaging by a nuclear factor κB inhibitor parthenolide. J Pharm Exp Ther 2005; 315: 624-30.
47. Tassorelli C, Greco R, Morazzoni F, Riva A, Sandrini C, Nappi G. Parthenolide is the component of Tanacetum parthenium that inhibits nitroglycerin-induced Fos activation: studies in an animal model of migraine. Cephalalgia 2005; 25: 612-21.